Paper Details

  1. Home
  2. Paper Details

Oral Administration of Meloxicam and Flunixin Meglumine Have Similar Analgesic Effects After Lipopolysaccharide-Induced Inflammatory Response in Thoroughbred Horses.

Author: KusanoKanichi, MatsudaHiroshi, MitaHiroshi, MuranakaMasanori, NagashimaTsuyoshi, SatoHiroaki, TanakaAkane, UrayamaShuntaro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Flunixin meglumine (FM), a nonselective cyclooxygenase (COX) inhibitor, is commonly used for equine systemic inflammatory response syndrome (SIRS)/endotoxemia. This study compared the effects of meloxicam (MX), a COX-2 selective inhibitor, with FM in horses with LPS-induced SIRS. Both MX and FM effectively reduced pain scores and body temperature, but MX showed a more favorable effect on TNF-α and cortisol levels. These findings suggest that MX may be a beneficial alternative to FM in horses with SIRS/endotoxemia.
Paper Details　
Original Abstract of the Article :
Flunixin meglumine (FM), a nonselective cyclooxygenase (COX) inhibitor, is most frequently selected for the treatment of equine systemic inflammatory response syndrome (SIRS)/endotoxemia. However, FM has considerable adverse effects on gastrointestinal function. The aims of this study were to compar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jevs.2022.104205

データ提供：米国国立医学図書館（NLM）

Meloxicam vs. Flunixin Meglumine: A Showdown in Equine Pain Management

This study compares the analgesic effects of meloxicam and flunixin meglumine, two common medications used to manage pain in horses. The researchers used a lipopolysaccharide (LPS)-induced inflammatory response model in thoroughbred horses to evaluate the analgesic efficacy of both drugs. The study found that both meloxicam and flunixin meglumine were effective in reducing pain and inflammation, with no significant difference in their analgesic effects.

Two Powerful Allies: Similar Efficacy, Different Profiles

This study demonstrates that both meloxicam and flunixin meglumine are effective analgesics in horses. However, meloxicam, being a COX-2 selective inhibitor, may offer a potential advantage by reducing the risk of gastrointestinal side effects compared to flunixin meglumine, a nonselective COX inhibitor.

Riding Through the Desert of Equine Pain

Imagine a horse facing the harsh desert conditions of pain and inflammation. Meloxicam and flunixin meglumine act as powerful companions, offering relief and helping the horse to navigate through this challenging terrain. Choosing the right companion depends on individual needs and considerations.

Dr.Camel's Conclusion

This study provides valuable insights into the use of meloxicam and flunixin meglumine in equine pain management. While both drugs are effective, meloxicam's COX-2 selectivity may offer a potential advantage by reducing the risk of gastrointestinal side effects.

Date :
  1. Date Completed 2023-02-14
  2. Date Revised 2023-04-05
Further Info :

Pubmed ID

36586521

DOI: Digital Object Identifier

10.1016/j.jevs.2022.104205

Related Literature

Article Analysis
・Effects of meloxicam
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.